Companies › Oxford BioMedica
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RetinoStat Adeno-associated virus (AAV) vector delivering soluble fms-like tyrosine kinase-1 (sFLT1) | SFLT1 | Phase 1 | Age-Related Macular Degeneration | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01678872 | RetinoStat | Phase 1 | Age-Related Macular Degeneration | Ophthalmology | Mar 2029 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.